Archive for Profitability

Yet again there is more downward pressure on dispensaries as the Category M figures for January 2025 show an overall decrease in price for 405 products with 297 of those….....

Using the Brand Comparisons data form the Profitability section of the Dispex website, we will be publishing Dispensary Friendly formularies for a number of conditions, starting with Adult Asthma. There...

Click here to login and view. ​

Using the Brand Comparisons data from the Dispex website, we will be publishing dispensary friendly formularies for a number of conditions. Members can login here to see the COPD section.

Dispensary Friendly Formulary – another resource to help Dispex members By Dr Philip Koopowitz – Dispex & Hexagon6 Dispex has a wealth of resources to assist practices in creating their...

Using the Brand Comparisons data form the Profitability section of the Dispex website, we will be publishing Dispensary Friendly formularies for a number of conditions, starting with Adult Asthma. There...

 UPDATE from Dispex 25th October 2024 By Dr Philip Koopowitz – Dispex & Hexagon6 Following clarification from NHSBSA, the reclassification of Nexplanon as “Attracts an Administration Fee” only comes into...

By Dr Philip Koopowitz – Dispex & Hexagon6 The Dispensing Fee Scale from 1st October 2024 has been published and will impose a miniscule reduction in the Dispensing Fees. This...

The DHSC has published an updated Category M price list starting on 1 August and continuing until the end of September. According to the NHSBSA Prescription Services website: “Due to...